Company intelligence / Profile preview

Saham Pharma

Ownership: Private
Development stage: Commercial

Overview

Saham Pharma was a leading Moroccan pharmaceutical company specializing in the production of antibiotics and distribution of medicines, including solutions for rare disease management. It was the main hospital provider in Morocco before being acquired by SPE Capital Partners and rebranded as Amanys Pharma in 2020.[2][3][7]

Therapeutic areas: Rare DiseasesInfectious Diseases
Modalities: Small molecules (notably antibiotics)orphan drugs[2][3]
Industry: Biotech

Partnerships

Proparco co-investor with SPE Capital Partners during acquisition[7].

Beyond the preview

Go deeper on Saham Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saham Pharma.

Explore the full profile